AVITA Medical Inc
AVH: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|&$><b$ | LOCK|Df | LOCK|CfWL%c# |
Avita Medical Earnings: Fair Value Estimate Cut on Unlikely Vitiligo Reimbursement Support
Avita Medical's first-quarter 2025 sales grew just 1% on fourth-quarter 2024 to USD 18 million. Avita is also suspending its vitiligo efforts given uncertainty of achieving reimbursement support and cutting costs to focus on acute wound care. Shares fell as much as 20% on the result.
